Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
22
9
2020
medline:
12
10
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
To investigate the association of blood pressure BP excursions, defined as greater than 185 SBP or greater than 105 DBP, with the probability of intracranial hemorrhage (ICH) and worse functional outcomes in patients with acute ischemic stroke (AIS) treated with tissue plasminogen activator (tPA). We performed a post hoc analysis of the CLOTBUST-ER trial. Serial BP measurements were conducted using automated cuff recording according to the recommended BP protocol guidelines for tPA administration. The outcomes were prespecified efficacy and safety endpoints of CLOTBUST-ER. The mean number of serial BP recordings per patient was 37. Of the 674 patients, 227 (34%) had at least one BP excursion (>185/105 mmHg) during the first 24 h following tPA-bolus. The majority of BP excursions (46%) occurred within the first 75 min from tPA-bolus. Patients with at least one BP excursion in the first 24 h following tPA bolus had significantly lower rates of independent functional outcome at 90 days (31 vs. 40.1%, P = 0.028). The total number of BP excursions was associated with decreased odds of 24-h clinical recovery (OR = 0.88, 95% CI:0.80-0.96), 24-h neurological improvement (OR = 0.87, 95% CI: 0.81-0.94), 7-day functional improvement (common OR = 0.92, 95% CI: 0.87-0.97), 90-day functional improvement (common OR = 0.94, 95% CI: 0.88-0.98) and 90-day independent functional outcome (OR = 0.90, 95% CI: 0.82-0.98) in analyses adjusted for potential confounders. DBP excursions were independently associated with increased odds of any intracranial hemorrhage (OR = 1.26, 95% CI: 1.04-1.53). BP excursions above guideline thresholds during the first 24 h following tPA administration for AIS are common and are independently associated with adverse clinical outcomes.
Identifiants
pubmed: 32956103
pii: 00004872-202102000-00011
doi: 10.1097/HJH.0000000000002628
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-272Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145–1150.
Malhotra K, Ahmed N, Filippatou A, Katsanos AH, Goyal N, Tsioufis K, et al. Association of elevated blood pressure levels with outcomes in acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. J Stroke 2019; 21:78–90.
Tsivgoulis G, Frey JL, Flaster M, Sharma VK, Lao AY, Hoover SL, et al. Pretissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke 2009; 40:3631–3634.
Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32:12–16.
Kellert L, Rocco A, Sykora M, Hacke W, Ringleb PA. Frequency of increased blood pressure levels during systemic thrombolysis and risk of intracerebral hemorrhage. Stroke 2011; 42:1702–1706.
Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A. VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013; 44:727–733.
Berge E, Cohen G, Lindley RI, Sandercock P, Wardlaw JM, Sandset EC, Whitley W. Effects of blood pressure and blood pressure-lowering treatment during the first 24 hours among patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke. Stroke 2015; 46:3362–3369.
Alexandrov AV, Köhrmann M, Soinne L, Tsivgoulis G, Barreto AD, Demchuk AM, et al. CLOTBUST-ER Trial Investigators. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurol 2019; 18:338–347.
Schellinger PD, Alexandrov AV, Barreto AD, Demchuk AM, Tsivgoulis G, Kohrmann M, et al. CLOTBUST-ER Trial Investigators. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial. Int J Stroke 2015; 10:1141–1148.
Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870–947.
Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke V, et al. SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275–282.
Ritter MA, Kimmeyer P, Heuschmann PU, Dziewas R, Dittrich R, Nabavi DG, Ringelstein EB. Blood pressure threshold violations in the first 24 h after admission for acute stroke: frequency, timing, predictors, and impact on clinical outcome. Stroke 2009; 40:462–468.
Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009; 66:28–38.
Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, et al. SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40:2442.
Tsivgoulis G, Saqqur M, Sharma VK, Lao AY, Hill MD, Alexandrov AV, et al. CLOTBUST Investigators. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke 2007; 38:961–966.
Lyerly MJ, Albright KC, Boehme AK, Bavarsad SR, Houston JT, Rawal PV, et al. Safety of protocol violations in acute stroke tPA administration. J Stroke Cerebrovasc Dis 2014; 23:855–860.
Wu W, Huo X, Zhao X, Liao X, Wang F C, Pan Y, et al. TIMS-CHINA investigators. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016; 11:e0144260.
Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al. ENCHANTED Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet 2019; 393:877–888.
Sandset EC, Fischer U. Blood pressure lowering in acute ischaemic stroke thrombolysis. Lancet 2019; 393:849–850.
Tsivgoulis G, Kotsis V, Giannopoulos S. Intravenous thrombolysis for acute ischaemic stroke: effective blood pressure control matters. Int J Stroke 2011; 6:125–127.
Mattle HP, Kappeler L, Arnold M, Fischer U, Nedeltchev K, Remonda L, et al. Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke 2005; 36:264–268.
Hong L, Cheng X, Lin L, Bivard A, Ling Y, Butcher K, et al. INSPIRE Study Group. The blood pressure paradox in acute ischemic stroke. Ann Neurol 2019; 85:331–339.